Tg Therapeutics (TGTX) Shares Outstanding (2010 - 2026)

Tg Therapeutics' Shares Outstanding (Entity) history runs 15 years deep, the most recent figure standing at $160.0 million for Q1 2026.

• On a quarterly basis, Shares Outstanding (Entity) rose 0.77% year-over-year to $160.0 million in Q1 2026; TTM through Mar 2026 was $160.0 million, a 0.77% increase from a year earlier, with the FY2025 full-year figure at $158.8 million, up 1.69% from the prior year.
• Shares Outstanding (Entity) grew to $160.0 million in Q1 2026 per TGTX's latest filing, from $158.8 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $160.0 million in Q1 2026 and bottomed at $144.6 million in Q1 2022.
• The 5-year median for Shares Outstanding (Entity) is $154.6 million (2024), against an average of $153.0 million.
• Across the five-year window, Shares Outstanding (Entity) advanced 4.19% in 2023 and gained 0.77% in 2026, its largest moves.
• Year by year, Shares Outstanding (Entity) stood at $146.4 million in 2022, then climbed by 3.44% to $151.5 million in 2023, then gained by 3.13% to $156.2 million in 2024, then gained by 1.69% to $158.8 million in 2025, then gained by 0.7% to $160.0 million in 2026.
• Per Business Quant, the three latest TGTX Shares Outstanding (Entity) figures stand at $160.0 million (Q1 2026), $158.8 million (Q4 2025), and $158.8 million (Q3 2025).